Healthcare resource utilization and costs associated with exacerbation or crisis in generalized myasthenia gravis
Recommended Citation
Silvestri N, Gandhi K, Cloutier M, Coteur G, Zhdanava M, El Khoury A, Boonmak P, Tardif-Samson A, Ait-Thiyaty M, Wang Y, Choudhry Z, Grover K. Healthcare resource utilization and costs associated with exacerbation or crisis in generalized myasthenia gravis. Eur J Neurol 2025; 32.
Document Type
Conference Proceeding
Publication Date
6-21-2025
Publication Title
Eur J Neurol
Abstract
Background and aims: Exacerbation and crisis are experienced by 38.5% and 2.1% of patients with generalized myasthenia gravis (gMG), respectively.1 While the overall burden of gMG is documented, the impact of exacerbation/crisis remains unclear, hindering efforts to address unmet healthcare needs. Methods: Adults with incident gMG (MG diagnosis by a neurologist; 12-month washout before the first MG diagnosis) and > = 1 clinical event (exacerbation: primary MG diagnosis in an inpatient or emergency setting or any exacerbation-related diagnosis; or crisis: intubation) were identified from Komodo Research Database (01/2017-09/2023). Index date was the first clinical event following gMG. Patients had > = 12 months of insurance coverage pre- and post-index. Monthly per-patient healthcare resource utilization (HRU) and costs were described 12 months pre- and post-index. Results: Among 2,657 patients (mean age: 61.1 years; female: 47.5%), the first clinical event (exacerbation: 98.2%; crisis: 1.8%) were reported predominantly in the outpatient setting (55.2%) and, on average, 3.8 months after gMG diagnosis. Mean monthly inpatient days (0.75 vs. 0.29) and outpatient visits (3.44 vs. 2.47) increased post-index compared to pre-index. Mean monthly total healthcare costs increased twofold ($7,985 vs. $2,939), driven by pharmacy ($3,711 vs. $723) and inpatient costs ($2,420 vs. $943). HRU and costs peaked during the first month post-index; reaching $19,325, 3.21 inpatient days, and 4.88 outpatient visits and remained elevated compared to pre-index. Conclusion: Clinical events associated with gMG are resource-intensive, with both acute and long-term impacts. Findings underscore the importance of more effective and earlier treatments to achieve optimal disease control and reduce risk of crises/exacerbations.
Volume
32
